Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

@inproceedings{Glimelius2011PredictionOI,
  title={Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer},
  author={Bengt Glimelius and Hans Garmo and {\AA}ke Berglund and Lennart Fredriksson and Martin Berglund and Hugo Kohnke and Per Bystr{\"o}m and H. S\orbye and Mia Wadelius},
  booktitle={The Pharmacogenomics Journal},
  year={2011}
}
Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer. Irinotecan's active metabolite is inactivated by UDP-glucuronosyltransferase 1A1 (UGT1A1), which is deficient in Gilbert's syndrome. Irinotecan and metabolites are transported by P-glycoprotein, encoded by ABCB1. 5-FU targets folate metabolism through inhibition of thymidylate synthase (TYMS). Methylenetetrahydrofolate reductase (MTHFR) generates active folate necessary for haematopoiesis. We retrospectively… CONTINUE READING
53 Citations
54 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Estimation of the warfarin dose with clinical and pharmacogenetic data

  • RB Altman, N Eriksson, BF Gage, SE Kimmel, MT Lee
  • N Engl J Med
  • 2009

Similar Papers

Loading similar papers…